PTC Therapeutics PTCT · NASDAQ
$65.44 -0.35% (-$0.23)
Summary
40 / 100 · Bulios Score
What speaks for it
- Revenue grew by 35% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 24% this fiscal year.
- Operating profit covers the interest on its debt only 1.0 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 35% a year over 5 years. Over the last 3 years it grew by 35% a year. For the next fiscal year analysts expect revenue to fall by 24%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $106.0M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 18
- Hold 6
- Sell 2
Today's price within the analysts' price targets
The average target of $102.5 is 57% above today's price. 69% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration and License Revenue 55%
- Product 32%
- Royalty 13%
By region
- Non-US 57%
- UNITED STATES 43%
Collaboration and License Revenue brings in 55% of revenue. Product grew fastest, by 12% a year.
Segments in detail